🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hepatocellular Carcinoma (HCC)
Clinical trial register · China

Hepatocellular Carcinoma (HCC) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 24 Guangzhou 19 Shanghai 15 Wuhan 11 Hefei 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Tongji Hospital6 Fudan University4 Sun Yat-sen University4 Nanfang Hospital, Southern Medical University3 Anhui Provincial Hospital2
Site location
Beijing24 Guangzhou19 Shanghai15 Wuhan11 Hefei7
All 45 locations
Target enrolment
to

Hepatocellular Carcinoma (HCC) trials in China

93 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
NCT07732504Hepatocellular Carcinoma (HCC)
Tongji Hospital
Not applicable
2,000
Wuhan
2026-10-01
Recruiting
GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
NCT07795437Hepatocellular Carcinoma (HCC)
Peking University First Hospital
Not applicable
100
Beijing
2026-08-25
Not yet open
HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
NCT07780357Hepatocellular Carcinoma (HCC)
Beijing Friendship Hospital
Observational
2,000
Beijing
2026-08-20
Not yet open
Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
NCT07768085Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma
Shengjing Hospital
Not applicable
40,000
Shenyang
2026-08-17
Recruiting
Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
NCT07639138Hepatocellular Carcinoma (HCC)
Shunda Du
Phase 2
32
Beijing
2026-08-12
Recruiting
A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
NCT07070076Hepatocellular Carcinoma (HCC)
Li Qiang
Not applicable
286
Guangzhou
2026-08-01
Not yet open
The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
NCT07724951Hepatocellular Carcinoma (HCC)
Shanghai Zhongshan Hospital
Observational
400
Guangzhou, Nanning, Harbin, Qingdao, Shanghai, Kunming
2026-07-31
Recruiting
TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
NCT07658833Hepatocellular Carcinoma (HCC)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
120
Guangzhou
2026-07-01
Not yet open
Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
NCT07565415Hepatocellular Carcinoma (HCC), Cachexia, Anorexia, Malnutrition
DrugNanocrystalline Megestrol Acetate
Nanfang Hospital, Southern Medical University
Phase 2
88
Guangzhou
2026-06-22
Not yet open
68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
NCT07590336Hepatocellular Carcinoma (HCC)
Peking Union Medical College Hospital
Phase 1/2
100
Beijing
2026-06-01
Not yet open
NK521 in the Treatment of Advanced Solid Tumors
NCT07657416Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
DrugNK521 Cell
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1
18
Hefei
2026-06
Not yet open
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
NCT07537946Hepatocellular Carcinoma (HCC), Metastases
Tongji Hospital
Phase 3
400
Wuhan
2026-05-30
Not yet open
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
NCT07583316Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
Corregene Biotechnology Co., Ltd
Phase 1
192
Beijing
2026-05-29
Active, closed
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
NCT07466225Hepatocellular Carcinoma (HCC)
DrugsLenvatinib·Nivolumab
Peking University
Observational
150
Beijing
2026-05-29
Recruiting
Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
NCT07483359Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus
First Hospital of China Medical University
Phase 2
38
Shenyang
2026-05-20
Not yet open
Denosumab Strategy for Liver Cancer With Bone Metastases
NCT07537972Hepatocellular Carcinoma (HCC), Bone Metastases
DrugsDenosumab·Tislelizumab
Tongji Hospital
Phase 2
50
Wuhan
2026-05-01
Recruiting
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
NCT07677774Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT
The First Affiliated Hospital of Xiamen University
Not applicable
40
Xiamen
2026-05-01
Not yet open
Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions
NCT07582419Hepatocellular Carcinoma (HCC)
The First Hospital of Jilin University
Observational
1,424
Changchun
2026-04-30
Recruiting
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
NCT07381634Hepatocellular Carcinoma (HCC), IrAE
DrugOndansetron
First Affiliated Hospital of Wenzhou Medical University
Phase 2
134
Wenzhou
2026-04-30
Not yet open
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
NCT07537959Hepatocellular Carcinoma (HCC), Metastasis
Tongji Hospital
Not applicable
280
Wuhan
2026-04-30
Not yet open
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
NCT07537777Hepatocellular Carcinoma (HCC), First-line Targeted Therapy Failure, Oligometastatic Hepatocellular Carcinoma, Benmelstobart
Nanfang Hospital, Southern Medical University
Phase 2
29
Guangzhou
2026-04-20
Recruiting
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
NCT07463248Hepatocellular Carcinoma (HCC)
DrugsFecal Microbiota Transplantation·Tislelizumab
Wang Xin
Phase 2
64
Chengdu
2026-04-15
Recruiting
AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
NCT07538882Hepatocellular Carcinoma (HCC)
Beijing Tsinghua Chang Gung Hospital
Observational
108
Beijing
2026-04-13
Recruiting
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
NCT07413354Hepatocellular Carcinoma (HCC)
DrugsHuaier·Tislelizumab
Tongji Hospital
Phase 2
94
Wuhan
2026-04-01
Not yet open
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
NCT07487402Hepatocellular Carcinoma (HCC)
Zhejiang University
Phase EARLY_PHASE1
27
Hangzhou
2026-03-30
Recruiting
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
NCT07490262Hepatocellular Carcinoma (HCC)
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 2/3
680
Hefei, Shanghai
2026-03-27
Recruiting
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
NCT07422753Hepatocellular Carcinoma (HCC)
DrugIpilimumab N01
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hangzhou
2026-03-25
Recruiting
SBRT Versus Surgical Resection for Small HCC
NCT07381660Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 3
390
Guangzhou
2026-03-18
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
DrugsPumitamig·Ipilimumab
Bristol-Myers Squibb
Phase 1/2
198
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Nanyang
2026-03-16
Not yet open
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
NCT07392866Hepatocellular Carcinoma (HCC)
DrugsSH006·Regorafenib·Oxaliplatin·Capecitabine
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 2/3
120
Nanjing, Shanghai
2026-03-01
Active, closed
Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca
NCT07493070Hepatocellular Carcinoma (HCC)
Fujian Medical University Union Hospital
Not applicable
30
Fuzhou
2026-02-10
Not yet open
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
NCT07314372Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
86
Nanjing
2026-02-01
Active, closed
Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial
NCT07380633Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 2
90
Guangzhou
2026-01-23
Recruiting
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
NCT07154082Hepatocellular Carcinoma (HCC)
DrugTACE
Wei Zhang
Phase 2
27
Wuhan
2025-12-30
Recruiting
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
NCT07268131Hepatocellular Carcinoma (HCC)
Fudan University
Not applicable
30
Shanghai
2025-12-09
Recruiting
NWRD06 DNA Plasmid for HCC After Curative Resection.
NCT07324304Hepatocellular Carcinoma (HCC)
Newish Technology (Beijing) Co., Ltd.
Phase 2
30
Beijing, Harbin, Hangzhou
2025-12-08
Recruiting
DEB-TACE vs cTACE in HCC After TIPS
NCT07322848Hepatocellular Carcinoma (HCC), TACE, TIPS, DEB-TACE
First Affiliated Hospital, Sun Yat-Sen University
Phase 3
206
Guangzhou
2025-12-01
Recruiting
Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
NCT07436845Hepatocellular Carcinoma (HCC), Emotional Distress, HAIC(Hepatic Artery Infusion Chemotherapy), Immunotherapy
Nanfang Hospital, Southern Medical University
Observational
90
Guangzhou
2025-12-01
Not yet open
A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
NCT07239986Hepatocellular Carcinoma (HCC)
DrugBB102
Broadenbio Ltd., Co.
Phase 2
60
Hefei, Shanghai
2025-12
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650Hepatocellular Carcinoma (HCC)
DrugsYervoy·Opdivo
Shanghai Henlius Biotech
Phase 1
246
Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou
2025-11-25
Recruiting
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
NCT07331883Hepatocellular Carcinoma (HCC)
DrugsBevacizumab biosimilar·Tislelizumab
Ruijin Hospital
Phase 2
35
Sanming, Changchun, Shanghai
2025-11-17
Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
DrugGKL-006
Beijing Gene Key Life Technology Co., Ltd
Phase 2
48
Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou
2025-11-14
Recruiting
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
NCT07150624Hepatocellular Carcinoma (HCC), Liver Diseases
Anhui Provincial Hospital
Phase 4
96
Hefei
2025-11-10
Recruiting
Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
NCT07337460Hepatocellular Carcinoma (HCC)
Northern Jiangsu People's Hospital
Phase 2
30
Yangzhou
2025-11-01
Recruiting
Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
NCT07417800Hepatocellular Carcinoma (HCC), Artificial Intelligent, Adjuvant Chemoradiotherapy, TACE
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
11,000
Hangzhou
2025-11-01
Not yet open
A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
NCT07156617Hepatocellular Carcinoma (HCC)
Xuhua Duan
Observational
2,000
Haikou, Xingtai, Dengzhou, Jiaozuo, Kaifeng, Luoyang, Shangqiu, Zhengzhou
2025-10-01
Recruiting
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
NCT07012798Hepatocellular Carcinoma (HCC)
DrugsDurvalumab·Bevacizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-09-25
Recruiting
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
NCT07192185Hepatocellular Carcinoma (HCC)
DrugFolfox
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-09-17
Recruiting
A Phase I Study of CREPT-618 in Locally Advanced HCC
NCT07364357Hepatocellular Carcinoma (HCC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
13
Beijing
2025-09-15
Recruiting
A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
NCT07495215Hepatocellular Carcinoma (HCC)
DrugINeo-Vac-R01
Yinghua Xu
Phase 1/2
20
Hangzhou
2025-09-11
Recruiting
Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
NCT07337421Hepatocellular Carcinoma (HCC)
Northern Jiangsu People's Hospital
Phase 2
30
Yangzhou
2025-09-01
Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
NCT07170345Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI)
Chinese Academy of Sciences
Observational
400
Fuzhou, Guangzhou, Zhuhai, Nanning, Guiyang, Zhengzhou, Shenyang, Chengdu
2025-09-01
Not yet open
Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy
NCT07151326Hepatocellular Carcinoma (HCC)
National Health Research Institutes, Taiwan
Phase 2
60
2025-09
Recruiting
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
NCT07594964Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Gastric Cancer (GC)
DrugXH001
Shenzhen Xinhe Biomedical
Phase 1
48
Beijing
2025-08-25
Recruiting
Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
NCT07100392Hepatocellular Carcinoma (HCC)
Fudan University
Phase 2
141
Shanghai
2025-08-14
Active, closed
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
NCT07138885Hepatocellular Carcinoma (HCC), Second Line Treatment
Sun Yat-sen University
Phase 2
62
Guangzhou
2025-08-01
Recruiting
Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
NCT07077356Hepatocellular Carcinoma (HCC)
West China Hospital
Phase 1
15
Chengdu
2025-08-01
Recruiting
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
NCT06841172OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
Shandong Cancer Hospital and Institute
Phase 3
132
Jinan
2025-07-21
Recruiting
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
NCT07052253Hepatocellular Carcinoma (HCC)
DrugsTinengotinib·Cadonilimab·Bevacizumab
Akeso
Phase 2
100
Wuhan
2025-07-18
By invitation
JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
NCT06882876Hepatocellular Carcinoma (HCC)
Xiangya Hospital of Central South University
Phase 1
20
Changsha
2025-07-10
Recruiting
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
NCT07186621Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE
DrugTislelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
286
Beijing
2025-07-10
Recruiting
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
NCT07047586Hepatocellular Carcinoma (HCC)
DrugsLenvatinib·Tislelizumab
Fudan University
Phase 2
146
Shanghai
2025-07-02
Recruiting
Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
NCT07059936Hepatocellular Carcinoma (HCC)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
350
Wuhan
2025-07
Recruiting
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034Hepatocellular Carcinoma (HCC)
DrugABSK-011
Abbisko Therapeutics Co, Ltd
Phase 2
141
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guilin, Liuzhou, Nanning
2025-06-13
Not yet open
Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
NCT07010588Hepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI), Randomized Controlled Trial
Peking University People's Hospital
Not applicable
1,389
Beijing, Chongqing, Handan, Harbin, Wuhan, Changchun, Jinan, Qingdao
2025-06
Recruiting
Electronic Symptom Monitoring of Patient-Reported Outcomes Among Patients With Hepatocellular Carcinoma During Immunotherapy (PRIME-HCC): Protocol for a Randomised Controlled Trial
NCT06938945Hepatocellular Carcinoma (HCC)
Wei Xiaoping
Not applicable
500
Haidian
2025-05-24
Recruiting
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
NCT06893887Hepatocellular Carcinoma(HCC)
Nanjing Tianyinshan Hospital
Not applicable
300
Nanjing
2025-05-22
Not yet open
Relationship Between FGF19 Overexpression and Disease Prognosis
NCT06938451Hepatocellular Carcinoma (HCC)
Beijing Tsinghua Chang Gung Hospital
Observational
100
Beijing
2025-05-01
Active, closed
A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
NCT07713290Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
DrugGKL-006
Beijing Gene Key Life Technology Co., Ltd
Phase 1
6
Beijing, Taiyuan
2025-04-03
Active, closed
Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection
NCT06934070Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC) Prognosis
Qiang Xu
Observational
287
Nanchang
2025-04-03
Recruiting
Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
NCT07832006Hepatocellular Carcinoma (HCC)
Shunda Du
Phase 2
30
Beijing
2025-04-01
Recruiting
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
NCT06860490Hepatocellular Carcinoma (HCC)
DrugsBevacizumab biosimilar·Tislelizumab
Fudan University
Phase 2
164
Shanghai
2025-03-18
Recruiting
Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
NCT06741020Hepatocellular Carcinoma (HCC)
Zhejiang Cancer Hospital
Phase 1/2
10
Hangzhou
2025-03-01
Active, closed
Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial
NCT06842563Hepatocellular Carcinoma (HCC)
Singlera Genomics Inc.
Observational
900
Shanghai
2025-02-25
Recruiting
Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
NCT06861114Hepatocellular Carcinoma (HCC)
Zhujiang Hospital
Observational
38
Guangzhou
2025-02-20
Recruiting
Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
NCT06762782Hepatocellular Carcinoma (HCC), Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation
The First Affiliated Hospital with Nanjing Medical University
Phase 2
276
Nanjing
2025-02
Recruiting
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
NCT06746194Hepatocellular Carcinoma (HCC)
Ruijin Hospital
Observational
40
Shanghai
2024-12-03
Recruiting
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
NCT06644937Hepatocellular Carcinoma (HCC)
Zhujiang Hospital
Phase 2/3
30
Guangzhou
2024-11-29
Recruiting
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
NCT06653062Hepatocellular Carcinoma (HCC)
Tongji Hospital
Observational
50
Wuhan
2024-11-18
Recruiting
Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
NCT06652243Hepatocellular Carcinoma (HCC)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
12
Shanghai
2024-11-18
Recruiting
Mts105 for Advanced Hepatocellular Carcinoma
NCT06689540Liver Cancer, Adult, Metastatic Liver Cancers, HCC - Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)
Shen Lin
Phase 1
14
Beijing
2024-11-18
Not yet open
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
NCT06641453Hepatocellular Carcinoma (HCC)
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2024-11-15
Not yet open
Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC
NCT06639971Hepatocellular Carcinoma (HCC)
Shanghai Zhongshan Hospital
Observational
500
Shanghai
2024-11-01
Not yet open
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
NCT06685354Hepatocellular Carcinoma (HCC)
Henan Cancer Hospital
Phase 2
11
Zhengzhou
2024-11
Recruiting
Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
NCT06664996Hepatocellular Carcinoma (HCC)
West China Hospital
Phase 2
33
Chengdu
2024-10-15
Active, closed
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
NCT06487559Hepatocellular Carcinoma (HCC)
AbbVie
Phase 1
3
Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang
2024-09-11
By invitation
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
NCT06712017Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
GrandPharma (China) Co., Ltd.
Observational
100
Guangzhou, Jinan, Xi’an, Beijing, Shanghai
2024-08-22
Active, closed
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
NCT06632106Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC)
First Hospital of China Medical University
Observational
97
Shenyang
2024-08-16
Recruiting
An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
NCT07101237Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC), Primary Liver Cancer
Peking Union Medical College Hospital
Observational
308
Beijing
2024-08-01
Active, closed
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
NCT04639180Hepatocellular Carcinoma (HCC)
DrugsRivoceranib·Apatinib·Tislelizumab
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
687
Chongqing, Nanjin, Guiyang, Shanghai, Tianjin
2021-04-01
Recruiting
Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
NCT07782632Hepatocellular Carcinoma (HCC)
Anhui Provincial Hospital
Observational
467
Hefei
2019-01-01
Recruiting
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
NCT06876753Hepatocellular Carcinoma (HCC)
Zhongda Hospital
Observational
300
Nanjing
2018-06-01
Active, closed
Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging
NCT07581769Hepatocellular Carcinoma (HCC), Downstaging, Liver Resection, Lenvatinib
First Affiliated Hospital, Sun Yat-Sen University
Observational
500
Guangzhou
2018-01-01
Rows per page Showing 1–93 of 93
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/hepatocellular-carcinoma-hcc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 93 of those studies listing the condition Hepatocellular Carcinoma (HCC).

How many Hepatocellular Carcinoma (HCC) trials are recruiting in China?

56 of the 93 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 24 have not yet opened recruitment, 11 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hepatocellular Carcinoma (HCC)), 93 studies
PhaseStudiesRecruitingShare
Phase 2312233.3%
Observational241225.8%
Not applicable11611.8%
Phase 1959.7%
Phase 3646.5%
Phase 1/2535.4%
Phase 2/3323.2%
Phase EARLY_PHASE1313.2%
Phase 4111.1%

Most active sponsors

Lead sponsors with the most studies (Hepatocellular Carcinoma (HCC))
Lead sponsorStudiesRecruiting
Tongji Hospital62
Fudan University44
Sun Yat-sen University42
Nanfang Hospital, Southern Medical University31
Anhui Provincial Hospital22
Beijing Gene Key Life Technology Co., Ltd21
Beijing Tsinghua Chang Gung Hospital21
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
First Affiliated Hospital, Sun Yat-Sen University21
First Hospital of China Medical University21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.